|
Summary Information: Syndax Pharmaceuticals Inc. Common Stock NASDAQ:SNDX |
  admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.
__The following are links to various summary and news pages for __Syndax Pharmaceuticals Inc. Common Stock [ SNDX ]. __Note: Some Links might not have information for the company. |
|